ROKIT Healthcare, a bio-medical company seeking to list on the KOSDAQ, has set the public offering price at 11,000 won.
On the 22nd, ROKIT Healthcare noted that it conducted demand forecasting for domestic and foreign institutional investors from the 14th to the 18th over five business days, confirming the public offering price at the lower end of the desired range of 11,000 won.
ROKIT Healthcare plans to raise a total of 1.65 million shares in this listing and previously presented a desired public offering price range of 11,000 to 13,000 won with its listing underwriter, SK Securities.
A total of 1,104 institutions participated in the demand forecasting for institutional investors, with over 40%, or 442 institutions, bidding at 11,000 won. The number of institutions offering bids below 11,000 won reached 352 (31.88%).
The competition ratio was recorded at 368.45 to 1. Approximately 430 million shares were requested for a maximum of 1.17 million shares aimed at institutional investors.
ROKIT Healthcare was established in 2012 as a specialized company in AI-based ultra-personalized organ regeneration platforms. It developed the world’s first bio-ink production kit for ultra-personalization and successfully commercialized the organ regeneration platform.
The company plans to utilize the public offering funds to expand the application scope of the successfully commercialized organ regeneration platform to areas such as skin cancer, burns, cartilage, and kidneys. Last year's revenue was 13.1 billion won, with an operating loss of 5.6 billion won.
With the public offering price confirmed at the lower end, the public offering amount has decreased from the previously expected maximum of 21.5 billion won to 17.2 billion won. The market capitalization after listing is estimated at 169.6 billion won.
Meanwhile, ROKIT Healthcare will conduct a public subscription for general investors through SK Securities over two days on the 23rd and 24th, before listing on the KOSDAQ on the 12th of next month.